Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Ultragenyx Pharmaceutical Inc. (RARE) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 38,452.84 | 13,255.14 | 611.36 | 361.45 | -1,096.37 | 0.00 | 23.6280 | 43.26 | -0.8330 | -20.1747 | -0.08 | -0.07 | 6.8758 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Apellis Pharmaceuticals, Inc. APLS | 30.77 | 3.02 10.88% | 2,660 vs. 2,876 | 3,827.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| United Therapeutics Corporation UTHR | 372.89 | 5.53 1.51% | 240 vs. 357 | 16,647.00 | 677.00 | 306.00 | 338.00 | 6,333.00 | 6.5200 | 8.7477 | 0.0000 | 0.8924 | 0.4524 | 0.0574 | 0.0472 | 3.5035 | 44.00 | ||
| Incyte Corporation INCY | 71.72 | 1.33 1.89% | 1,521 vs. 2,070 | 13,816.00 | 880.00 | 169.00 | 209.00 | 329.00 | 0.7600 | 18.7480 | 0.0000 | 0.9308 | 0.1925 | 0.0314 | 0.0238 | 3.2913 | 192.00 | ||
| Alnylam Pharmaceuticals, Inc. ALNY | 244.89 | -1.91 -0.77% | 450 vs. 862 | 31,586.00 | 494.00 | -65.00 | -94.00 | -7,075.00 | -0.5200 | -73.3326 | 0.0000 | 0.8665 | -0.1334 | 0.3007 | -0.0172 | 2.8593 | 128.00 | ||
| Ultragenyx Pharmaceutical Inc. RARE | 47.24 | 1.22 2.65% | 572 vs. 716 | 4,362.00 | 108.00 | -170.00 | -203.00 | -3,558.00 | -2.0300 | -5.7986 | 0.0000 | 0.7576 | -1.5683 | -1.2169 | -0.1306 | 2.1127 | 92.00 | ||
| Revolution Medicines, Inc. RVMD | 56.75 | -0.03 -0.05% | 1,139 vs. 1,174 | 9,546.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.